Deutsche Bank AG lowered its position in Pfizer Inc. (NYSE:PFE – Free Report) by 9.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 36,565,859 shares of the biopharmaceutical company’s stock after selling 3,686,257 shares during the period. Pfizer makes up approximately 0.7% of Deutsche Bank AG’s investment portfolio, making the stock its 23rd biggest holding. Deutsche Bank AG owned approximately 0.65% of Pfizer worth $1,212,890,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. State Street Corp raised its stake in shares of Pfizer by 1.9% during the second quarter. State Street Corp now owns 287,201,692 shares of the biopharmaceutical company’s stock valued at $10,534,558,000 after acquiring an additional 5,374,611 shares in the last quarter. Moneta Group Investment Advisors LLC increased its holdings in Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares during the period. Geode Capital Management LLC increased its holdings in Pfizer by 2.7% during the second quarter. Geode Capital Management LLC now owns 112,872,506 shares of the biopharmaceutical company’s stock valued at $4,129,431,000 after buying an additional 3,019,727 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares during the period. Finally, Morgan Stanley increased its holdings in Pfizer by 10.3% during the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after buying an additional 7,419,929 shares during the period. Institutional investors own 68.05% of the company’s stock.
Pfizer Stock Performance
Shares of NYSE PFE traded down $0.01 during mid-day trading on Friday, hitting $27.56. The stock had a trading volume of 29,062,706 shares, compared to its average volume of 45,319,060. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.05 and a current ratio of 2.38. The company has a 50 day moving average of $28.19 and a two-hundred day moving average of $31.41. Pfizer Inc. has a twelve month low of $25.76 and a twelve month high of $44.20. The firm has a market cap of $155.62 billion, a PE ratio of 76.56, a PEG ratio of 1.22 and a beta of 0.62.
Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.61% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the firm earned $1.14 EPS. The firm’s revenue was down 41.3% on a year-over-year basis. Research analysts predict that Pfizer Inc. will post 2.23 EPS for the current fiscal year.
Pfizer Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 1st. Shareholders of record on Friday, January 26th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.10%. This is a positive change from Pfizer’s previous quarterly dividend of $0.41. The ex-dividend date of this dividend is Thursday, January 25th. Pfizer’s dividend payout ratio is presently 466.67%.
Insider Buying and Selling at Pfizer
In other Pfizer news, Director Scott Gottlieb purchased 3,000 shares of the stock in a transaction on Friday, December 15th. The shares were bought at an average cost of $26.47 per share, with a total value of $79,410.00. Following the completion of the acquisition, the director now owns 9,000 shares in the company, valued at $238,230. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the stock. Jefferies Financial Group raised shares of Pfizer from a “hold” rating to a “buy” rating and lifted their price objective for the company from $38.00 to $39.00 in a report on Monday, October 16th. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. JPMorgan Chase & Co. cut their price objective on shares of Pfizer from $36.00 to $34.00 and set a “neutral” rating on the stock in a report on Monday, October 16th. Truist Financial cut their price target on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. Finally, BMO Capital Markets cut their price target on shares of Pfizer from $44.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, October 16th. Eleven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $36.93.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.